The FDA's Pharmacy Compounding Advisory Committee voted 8-6 on July 23, 2026, with one abstention, to recommend adding BPC-157 to the Section 503A bulk drug substances list, advancing it from prior Category 2 status after withdrawal of safety nominations in April. FDA career staff had advised against inclusion, citing insufficient human data on safety, efficacy, characterization, and proposed routes of administration. The nonbinding advisory vote does not itself authorize compounding or shift the substance to Category 1, which instead requires formal FDA rulemaking with notice-and-comment procedures that historically span eight to twelve months or longer. Committee composition drew scrutiny over members' ties to peptide clinics, while broader context includes policy emphasis on expanding access to certain unapproved substances under current administration priorities. No further PCAC action or proposed rule has been announced as of late August 2026.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · UpdatedNEW
Aug 31, 2026
August 31, 2026
3%
December 31, 2026
51%
$2,984 Vol.
August 31, 2026
$1,268 Vol.
3%
December 31, 2026
$1,716 Vol.
51%
This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.The FDA's Pharmacy Compounding Advisory Committee voted 8-6 on July 23, 2026, with one abstention, to recommend adding BPC-157 to the Section 503A bulk drug substances list, advancing it from prior Category 2 status after withdrawal of safety nominations in April. FDA career staff had advised against inclusion, citing insufficient human data on safety, efficacy, characterization, and proposed routes of administration. The nonbinding advisory vote does not itself authorize compounding or shift the substance to Category 1, which instead requires formal FDA rulemaking with notice-and-comment procedures that historically span eight to twelve months or longer. Committee composition drew scrutiny over members' ties to peptide clinics, while broader context includes policy emphasis on expanding access to certain unapproved substances under current administration priorities. No further PCAC action or proposed rule has been announced as of late August 2026.
This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
Market Opened: Jun 22, 2026, 10:10 PM ET
Volume
$2,984End Date
Jan 1, 2027Market Opened
Jun 22, 2026, 10:10 PM ETResolver
0x65070BE91...This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.The FDA's Pharmacy Compounding Advisory Committee voted 8-6 on July 23, 2026, with one abstention, to recommend adding BPC-157 to the Section 503A bulk drug substances list, advancing it from prior Category 2 status after withdrawal of safety nominations in April. FDA career staff had advised against inclusion, citing insufficient human data on safety, efficacy, characterization, and proposed routes of administration. The nonbinding advisory vote does not itself authorize compounding or shift the substance to Category 1, which instead requires formal FDA rulemaking with notice-and-comment procedures that historically span eight to twelve months or longer. Committee composition drew scrutiny over members' ties to peptide clinics, while broader context includes policy emphasis on expanding access to certain unapproved substances under current administration priorities. No further PCAC action or proposed rule has been announced as of late August 2026.
This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
Volume
$2,984End Date
Jan 1, 2027Market Opened
Jun 22, 2026, 10:10 PM ETResolver
0x65070BE91...The FDA's Pharmacy Compounding Advisory Committee voted 8-6 on July 23, 2026, with one abstention, to recommend adding BPC-157 to the Section 503A bulk drug substances list, advancing it from prior Category 2 status after withdrawal of safety nominations in April. FDA career staff had advised against inclusion, citing insufficient human data on safety, efficacy, characterization, and proposed routes of administration. The nonbinding advisory vote does not itself authorize compounding or shift the substance to Category 1, which instead requires formal FDA rulemaking with notice-and-comment procedures that historically span eight to twelve months or longer. Committee composition drew scrutiny over members' ties to peptide clinics, while broader context includes policy emphasis on expanding access to certain unapproved substances under current administration priorities. No further PCAC action or proposed rule has been announced as of late August 2026.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated
Beware of external links.
Beware of external links.
Frequently Asked Questions